Syncona might have hoped for a bigger payday with the prostate imaging specialist, but it has plenty more irons in the fire.
Shares in generics firms tumble in the wake of a huge lawsuit in the US alleging industry-wide price fixing, signalling many more years of pain for this sector.
Johnson & Johnson’s $3.4bn move for the robotic surgery specialist Auris Health could be bad news for its Verb Surgical joint venture.
Earlier this year Glaxosmithkline looked to be going all-in for consumer health domination, but today it moved to leave the space entirely and focus on the thing that…
Mainstay Medical still hopes for US approval of its Reactiv8 device for chronic back pain despite trial failure.